Literature DB >> 15756533

[Therapy for recurrent testicular cancer].

M Kuczyk1, M Horstmann, A Merseburger, J Beyer.   

Abstract

In the case of an insufficient response to primary treatment or a tumor relapse, regardless of an initially complete remission, conventional as well as high dose chemotherapy regimens are available as salvage therapy for metastatic germ cell tumors. A multimodal approach should include the radiation of simultaneously occurring brain metastases as well as the surgical resection of residual tumour masses still detectable after completion of chemotherapy. Nowadays, an attempt is made to adjust the salvage modality selected to the individual situation according to a risk stratification of patients. However, a recurrence-free survival of 50% is worse when compared with that observed after primary chemotherapy. Salvage therapy should be reserved for specialized centres due to the increased complexity of a salvage approach and a significantly increased therapy-induced morbidity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756533     DOI: 10.1007/s00120-005-0784-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  27 in total

1.  High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

Authors:  J Beyer; A Kramar; R Mandanas; W Linkesch; A Greinix; J P Droz; J L Pico; A Diehl; C Bokemeyer; H J Schmoll; C R Nichols; L H Einhorn; W Siegert
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

2.  Treatment of brain metastases in patients with testicular cancer.

Authors:  C Bokemeyer; P Nowak; A Haupt; B Metzner; H Köhne; J T Hartmann; L Kanz; H J Schmoll
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.

Authors:  P J Loehrer; R Lauer; B J Roth; S D Williams; L A Kalasinski; L H Einhorn
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

5.  Salvage chemotherapy for patients with advanced pure seminoma.

Authors:  Jacqueline Vuky; Satish K Tickoo; Joel Sheinfeld; Jennifer Bacik; Alison Amsterdam; Madhu Mazumdar; Victor Reuter; Dean F Bajorin; George J Bosl; Robert J Motzer
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

6.  Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

Authors:  C R Nichols; G Tricot; S D Williams; K van Besien; P J Loehrer; B J Roth; L Akard; R Hoffman; R Goulet; S N Wolff
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

7.  A phase II trial of paclitaxel in refractory germ cell tumors.

Authors:  A B Sandler; A Cristou; S Fox; S D Williams; C R Nichols; M Turns; B J Roth
Journal:  Cancer       Date:  1998-04-01       Impact factor: 6.860

8.  High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis.

Authors:  J Beyer; S Stenning; A Gerl; S Fossa; W Siegert
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

9.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

10.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Authors:  S D Fosså; S P Stenning; A Gerl; A Horwich; P I Clark; P M Wilkinson; W G Jones; M V Williams; R T Oliver; E S Newlands; G M Mead; M H Cullen; S B Kaye; G J Rustin; P A Cook
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.